An Interpretative Phenomenological Analysis of the use of psilocybin by veterans with symptoms of trauma

Authors FL Smith, JC Neill and V Wainwright Published September 7, 2022 Abstract Veterans are at increased risk of experiencing symptoms of trauma. Although many benefit from available treatments, some…

Continue ReadingAn Interpretative Phenomenological Analysis of the use of psilocybin by veterans with symptoms of trauma

A comparative study of the harms of nitrous oxide and poppers using the MCDA approach

Authors Plinio M Ferreira, Adam R Winstock, Anne Katrin Schlag, Brigitta Brandner, David Nutt,  Graeme Henderson, Ian Miller, Jan Van Amsterdam, Lawrence D Phillips, Polly Taylor, Rosalind Gittins, Steve Rolles…

Continue ReadingA comparative study of the harms of nitrous oxide and poppers using the MCDA approach

Psychedelic use predicts objective knowledge about climate change via increases in nature relatedness

Authors Christina Sagioglou, Matthias Forstmann Published October 2, 2022 Abstract Lifetime psychedelic substance use has previously been linked to nature relatedness and pro-environmental behaviour. Yet, participants’ responses to the self-report…

Continue ReadingPsychedelic use predicts objective knowledge about climate change via increases in nature relatedness

Examining the gender dimension in the non-medical use of over the counter and prescription only medication

Authors Rosalind Gittins, Joseph Tay Wee Teck, and Anna Madill Published October 26, 2022 Abstract There is concern regarding gender differences in problematic non-medical over the counter (OTC) and/or prescription…

Continue ReadingExamining the gender dimension in the non-medical use of over the counter and prescription only medication

The United Kingdom’s Psychoactive Substances Act 2016. Where are we now?

Authors Christopher Humphries Published November 14th, 2022 This narrative review describes the background to the introduction of the UK Psychoactive Substances Act 2016, and developments since the Home Office review…

Continue ReadingThe United Kingdom’s Psychoactive Substances Act 2016. Where are we now?

Medication sparing after medical cannabis initiation: A case study of a chronic pain patient in T21

Authors Peter Sunderland, David J Nutt, and Anne Katrin Schlag Published March 14th, 2023 Prescribed cannabinoids are legal in the UK and are increasingly being used for a variety of…

Continue ReadingMedication sparing after medical cannabis initiation: A case study of a chronic pain patient in T21

The use of chlordiazepoxide for outpatient gamma-butyrolactone (GBL) detoxification: An observational study

Authors Alfred Balston, Kuljit Hunjan, and Michael J Kelleher Published April 6th, 2023 Background Various detoxification regimens are used for gamma-hydroxybutyrate (GHB) and gamma-butyrolactone (GBL), including diazepam, barbiturates, baclofen and…

Continue ReadingThe use of chlordiazepoxide for outpatient gamma-butyrolactone (GBL) detoxification: An observational study

Decriminalisation of drug possession in Oregon: Analysis and early lessons

Authors Kellen Russoniello, Sheila P. Vakharia, Jules Netherland, Theshia Naidoo, Haven Wheelock, Tera Hurst and Saba Rouhani Published April 6th, 2023 Abstract In November 2020, Oregon voters approved Measure 110,…

Continue ReadingDecriminalisation of drug possession in Oregon: Analysis and early lessons

Characteristics of and 3-month health outcomes for people seeking treatment with prescribed cannabis

Authors Michael T Lynskey, Anne K Schlag, Alkyoni Athanasiou-Fragkouli, David Badcock and David J Nutt Published May 2nd, 2023 Abstract Medicinal cannabis has been legal in the UK since 2018…

Continue ReadingCharacteristics of and 3-month health outcomes for people seeking treatment with prescribed cannabis